Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

- 1. (currently amended) A method for predicting pharmacokinetic properties of molecules comprising the steps of:
 - (a) preparing 2D-structures of molecules used as a training set;
- (b) constructing a 2D-fingerprint by counting the number of structural descriptors that <u>may</u> potentially relate to a pharmacokinetic property <u>of a molecule set forth in the training set</u>, either manually or automatically using internally developed macro; wherein said structural descriptors consist of predefined 20 to 80 atoms/fragments or substructures;
- (c) analyzing the obtained 2D-fingerprint by a statistical analysis method to correlate with the pharmacokinetic property of the molecule to yield a quantitative structure-property relationship (QSPR) model; and
- (d) calculating the pharmacokinetic property of a trial molecule using the above obtained QSPR model.
- 2. (original) A method of Claim 1, wherein the pharmacokinetic property is absorption.
- 3. (withdrawn) A method of Claim 1, wherein the pharmacokinetic property is distribution.
- 4. (wthdrawn) A method of Claim 1, wherein the pharmacokinetic property is metabolism
- 5. (withdrawn) A method of Claim 1, wherein the pharmacokinetic property is excretion.
- 6. (currently amended) A method of Claim 1, wherein the internally developed macro comprises the macro script 2dfp.spl or 2dfp_abs.spl, written in <u>a language known</u> as SYBYLTM Programming Language (SPL).
 - 7. (currently amendedl) A system for predicting pharmacokinetic properties of

molecules comprising:

- (a) means for preparing 2D-structures of molecules used as a training set;
- (b) means for constructing a 2D-fingerprint by counting the number of structural descriptors that <u>may</u> potentially relate to a pharmacokinetic property <u>of a molecule set forth in the training set</u> wherein said structural descriptors consist of predefined 20 to 80 atoms/fragments or substructures;
- (c) means for analyzing the obtained 2D-fingerprint by a statistical analysis method to correlate with the pharmacokinetic property of the molecule to yield a quantitative structure-property relationship (QSPR) model; and
- (d) means for calculating the pharmacokinetic property of a trial molecule using the above obtained QSPR model.